Inhibition of Plasmodium falciparum in vitro by human immune serum provides needed information in understanding antimalarial immune mechanisms. Longitudinal, dry season-to-wet season changes in antimalarial activities were studied in sera isolated from 62 individuals living in an area of hyperendemic but unstable malaria. Highly synchronous cultures of P. falciparum were used to distinguish and quantitate two antimalarial activities, merozoite invasion inhibition, and intraerythrocytic parasite retardation. In 54% of the individuals, intraerythrocytic parasite retardation activity increased significantly, nearly threefold, in wet-season sera as compared with dry-season sera. Merozoite invasion inhibition activity was moderate and did not change seasonally. Merozoite invasion inhibition was, however, correlated to parasite-specific immunoglobulin G titers and total serum immunoglobulin G concentrations. These results confirm earlier studies which demonstrate two antimalarial activities in Sudanese sera and provide evidence that intraerythrocytic parasite retardation activity plays a role in antimalarial immunity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC263274 | PMC |
| http://dx.doi.org/10.1128/iai.45.2.505-510.1984 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emoquine-1: A Hybrid Molecule Efficient against Multidrug-Resistant Parasites, Including the Artemisinin-Resistant Quiescent Stage, and Also Active In Vivo.
J Med Chem
January 2025
Laboratoire de Chimie de Coordination du CNRS, LCC-CNRS, Inserm ERL 1289 MAAP, Université de Toulouse, 205 route de Narbonne, 31077 Toulouse cedex, France.
To challenge the multidrug resistance of malaria parasites, new hybrid compounds were synthesized and evaluated against laboratory strains and multidrug-resistant clinical isolates. Among these hybrids, emoquine-1 was the most active on proliferative , with IC values in the range of 20-55 nM and a high selectivity index with respect to mammalian cells. This drug retained its activity on several multiresistant field isolates from Cambodia and Guiana, exhibited no cross-resistance to artemisinin, and is also very active against the quiescent stage of the artemisinin-resistant parasites, three features that constitute the gold standard for new antimalarial drugs.
View Article and Find Full Text PDFYAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates.
Sci Rep
January 2025
Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-University of Barcelona), Rosselló 149-153, Barcelona, 08036, Spain.
We recently characterized the potent antiplasmodial activity of the aggregated protein dye YAT2150, whose presumed mode of action is the inhibition of protein aggregation in the malaria parasite. Using single-dose and ramping methods, assays were done to select Plasmodium falciparum parasites resistant to YAT2150 concentrations ranging from 3× to 0.25× the in vitro IC of the compound (in the two-digit nM range) and performed a cross-resistance assessment in P.
View Article and Find Full Text PDFDevelopment of a curcumin-piperine nanoparticle system using dissolving microneedles for transdermal drug delivery in malaria treatment: In vitro evaluation.
Int J Pharm
January 2025
Faculty of Pharmacy, Almarisah Madani University, Makassar, Indonesia; Department of Pharmacy and Pharmaceutical Technology, Almarisah Madani University, Makassar, Indonesia. Electronic address:
The combination of the active compounds curcumin and piperine (CP) is effective as an antimalarial; however, the solubility and bioavailability of CP are very low. This study aims to formulate CP in nanoparticles (NP), which are then fabricated into dissolving microneedles (DMN). The NPs were prepared with a concentration ratio of CP-Chitosan-So.
View Article and Find Full Text PDFSteroid-induced diabetes in lupus nephritis patients: Classic risk factors or a different type of diabetes?
Lupus
January 2025
Department of Medical Education, INCMNSZ, Ciudad de Mexico, Mexico.
Background: Glucocorticoids are frequently employed in systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus nephritis (LN), despite their many side effects, including steroid-induced diabetes (SID). Information regarding SID in SLE patients is quite scant.
Purpose: The aim of this study was to determine risk factors associated with the development of SID in patients with LN.
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus.
Lupus Sci Med
January 2025
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Objective: Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.
Methods: A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!